You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》高盛轻微下调德琪医药-B(06996.HK)目标价至23.45元 评级「买入」
阿思达克 03-31 14:23
高盛发表研究报告指,德琪医药-B(06996.HK)去年度亏损达5.73亿元人民币,较2019年度亏损1.09亿元人民币大幅扩大,差过该行预期亏损4.12亿元人民币,相信主要是由於汇兑损失所致。

期内研发开支增加两倍至3.48亿元人民币,该行指出,德琪医药目前有9个在研项目正进行临床实验,预期今年研发费用将增至5亿元人民币,并随着有更多项目进入注册阶段,销售开支亦会增加,因此相信在公司今年底至明年初推售首款产品的同时,2021至2023年的亏损料续轻微扩大。

该行指,德琪的抑制剂产品「XPOVIO」(selinexor)商业化进展顺利,去年取得美国两项批准,於去年销售额达7,600万美元,并已於新加坡、澳洲、中国内地、香港及韩国等多地提交新药上市申请,预期XPOVIO可於明年初在内地推出,并有可能获提前批准。

高盛维持对其「买入」评级,基於财务数据更新,目标价由23.61元轻微下调至23.45元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account